Business, energy, technology, markets and global industry news from Business News Today

pegevongitide

PharmaDeviceNews pegevongitide
Vasomune Therapeutics is positioning investigational Tie2 agonist Pegevongitide for potential use in vascular leak, severe trauma and CBRN-related medical emergencies ahead of its NATO NSPA presentation. Representative image.
Pharma & Biotech

Why Vasomune is taking its vascular leak drug to NATO before the clinical case is settled

Vasomune will present Pegevongitide at NATO’s CBRN forum, but clinical data and countermeasure readiness remain the decisive tests.

Read More
Vasomune Therapeutics is advancing Pegevongitide AV-001 as a potential vascular leak treatment for severe burns, shock, ARDS and combat-related injuries. Representative image.
Pharma & Biotech

Why Vasomune is taking its AV-001 vascular leak strategy into combat casualty medicine

Vasomune Therapeutics will present Pegevongitide at a major military health symposium, positioning vascular leak as a shared target across burns, shock, trauma and acute respiratory distress syndrome.

Read More
Pharma & Biotech

Vasomune Therapeutics advances vascular leak therapy as FDA allows pegevongitide burn trial program

FDA clears Vasomune Therapeutics’ IND for pegevongitide in severe burn resuscitation. Explore what this Tie2 therapy could change for vascular leak treatment.

Read More